About: Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 1989

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 1989 (uk) im Februar 1989 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en febreru de 1989 (ast) artikull shkencor i botuar më 01 shkurt 1989 (sq) scientific article published on 01 February 1989 (en)
publication date	wds:Q69579213-440AC59D-9FB4-4F8F-B771-EE61183D7278
publication date	1989-02-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q69579213-23AE5460-39A0-4582-AAD9-50A8F50D1870 wds:Q69579213-24D6D29E-7246-4823-833B-97B0894D0E23 wds:Q69579213-A69D6213-C2F8-4425-BAA8-B93CC8DE9028
author name string	A B Nethersell R T Oliver J M Bottomley
rdfs:label	Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma (en) Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma (nl) Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma (sq)
skos:prefLabel	Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma (en) Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma (nl) Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma (sq)
name	Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma (en) Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma (nl) Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma (sq)
title	wds:Q69579213-4EAFF53F-8A56-47B7-8757-4ACAEB342192
title	Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma (en)
page(s)	wds:Q69579213-95DCB2A9-0A5B-4C11-8533-0A19C445FD08
page(s)	128-131
instance of	wds:Q69579213-F5D6302B-462D-4F33-A08F-AE89B886B5B2
instance of	scholarly article
main subject	wds:Q69579213-49BE773B-94A0-4A38-8E83-E314DEC8DF33
main subject	renal carcinoma
PubMed ID	wds:Q69579213-C22F7489-093E-409A-A3A4-B48155FDFE54
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2702395
PubMed ID	2702395
published in	wds:Q69579213-F7F2F6CB-4C57-4085-8BB4-3BA743D9E5D9
published in	British Journal of Urology
issue	wds:Q69579213-67155139-88DA-472E-832A-F086DF92E905
volume	wds:Q69579213-BB6ADA32-901B-415E-AB4D-C383B0987FCF
issue	2
volume	63
DOI	wds:Q69579213-18AC93C0-A476-4BA7-BECF-D5451E662087
DOI	http://dx.doi.org/10.1111/J.1464-410X.1989.TB05147.X
DOI	10.1111/J.1464-410X.1989.TB05147.X
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q69579213
is cites work of	Immunotherapy for advanced renal cell cancer Immunotherapy for advanced renal cell cancer Targeted therapy for advanced renal cell carcinoma Immunotherapy for advanced renal cell cancer. State of the science: an update on renal cell carcinoma New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma Renal cell carcinoma Cytokine therapy in renal cell cancer Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen Allogeneic stem-cell transplantation in renal-cell carcinoma Renal Cell Carcinoma Induces Prostaglandin E2 and T-Helper Type 2 Cytokine Production in Peripheral Blood Mononuclear Cells Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. High-dose vitamin C therapy: renewed hope or false promise? Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now? A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma Immunotherapy of metastatic renal cell carcinoma Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review Evolving Immunotherapy Approaches for Renal Cell Carcinoma. The application of high-dose interleukin-2 for metastatic renal cell carcinoma Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial Relevance of the immune system in human urological malignancies: prospective for future clinical treatments Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects Stromal Infiltration of Tumor-Associated Macrophages Conferring Poor Prognosis of Patients with Basal-Like Breast Carcinoma. Role of cytokine therapy for renal cell carcinoma in the era of targeted agents. A Phase II study of high dose tamoxifen in progressive, metastatic renal cell Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response. Renal cell carcinoma and the use of sorafenib Genitourinary cancers in older adults. GM-CSF secretion in primary cultures of normal and cancerous human renal cells Systemic therapy for advanced renal cell carcinoma Novel immunotherapy in metastatic renal cell carcinoma Targeted therapy for metastatic renal cell carcinoma Sunitinib for advanced renal cell cancer Current status and perspective of antiangiogenic therapy for cancer: urinary cancer Advanced renal cell carcinoma [Is the cytoreductive nephrectomy still necessary in case of metastases?] New views on rejection mechanisms and their relevance to interleukin-2 as a treatment for renal cell cancer Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? Staging renal cell carcinoma Activity of a short course of interferon alpha for metastatic renal cell carcinoma--a phase-2 study The incidence, predictors, and survival of disappearing small renal masses on active surveillance Targeted therapy for advanced renal cell carcinoma Complete remission of extensive metastatic renal cancer following immunotherapy
is cites work of	wds:Q34328417-7E7848DD-082D-4FC3-9578-FEE6D56BE416 wds:Q40857084-E67CF953-F98B-49DC-B5FD-66BE516830E2 wds:Q41171087-731CC7BD-E110-49AF-A718-A67A8150F272 wds:Q94337029-C7317F9D-886A-4C83-B57D-0110197D5409 wds:Q24540522-FFD79A31-229D-440C-B85E-E31E8C020A3E wds:Q35166782-AF03C041-F54A-490E-80A2-6979FDFEF440 wds:Q24187300-96D2CBC5-48CF-4BAD-ADF9-40079B61C074 wds:Q36452714-AEBC41CC-951A-45E1-A1C7-B069BCE2F33F wds:Q37905583-BCE25A6D-9C2F-4822-A1B2-CCA5FCCD04D0 wds:Q40632475-3FF2D78D-E30D-4235-AFDF-C528CDDBA2FB

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software